Dr. Atkins on Results of Atezolizumab Plus Bevacizumab in RCC

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the results of a trial of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

Results of the combination of atezolizumab plus bevacizumab was active in both the atezolizumab- and sunitinib (Sutent)-refractory populations. Response rates ranged from 24% to 28%.

There was also a prolongation of progression-free survival in the second-line treatment, as compared with frontline treatment, says Atkins.